Clinuvel Pharmaceuticals Limited (ASX:CUV)
Australia
· Delayed Price · Currency is AUD 12.33
+0.17 (1.40%)
At close: Dec 5, 2025
Clinuvel Pharmaceuticals Cash Flow Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2016 - 2020 |
| Net Income | 36.17 | 35.64 | 30.6 | 20.88 | 24.73 | Upgrade
|
| Depreciation & Amortization | 1.15 | 1.09 | 0.74 | 0.72 | 0.82 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | - | 0.03 | 0.09 | Upgrade
|
| Stock-Based Compensation | 2 | 6.11 | 8.99 | 6.12 | 2.6 | Upgrade
|
| Other Operating Activities | -0.42 | 0.67 | -0.21 | 0.17 | 1.56 | Upgrade
|
| Change in Accounts Receivable | -1.22 | -4.02 | -6.01 | -0.11 | -9.48 | Upgrade
|
| Change in Inventory | 1.81 | -1.11 | -7.69 | 1.35 | -1.9 | Upgrade
|
| Change in Accounts Payable | 2.84 | -0.65 | 4.51 | -1.56 | - | Upgrade
|
| Change in Income Taxes | -1.3 | -0.24 | 8.81 | 7.18 | 0.1 | Upgrade
|
| Change in Other Net Operating Assets | -0.87 | 0.07 | -1.41 | -0.97 | -0.14 | Upgrade
|
| Operating Cash Flow | 41.1 | 37.05 | 36.91 | 39.87 | 19.26 | Upgrade
|
| Operating Cash Flow Growth | 10.91% | 0.38% | -7.42% | 107.00% | 35.76% | Upgrade
|
| Capital Expenditures | -0.3 | -5.58 | -1.03 | -0.43 | -0.85 | Upgrade
|
| Investment in Securities | -47.42 | -23.46 | -30.82 | - | - | Upgrade
|
| Investing Cash Flow | -47.72 | -29.03 | -31.85 | -0.43 | -0.85 | Upgrade
|
| Long-Term Debt Repaid | -0.18 | -0.35 | -0.26 | -0.27 | -0.2 | Upgrade
|
| Net Debt Issued (Repaid) | -0.18 | -0.35 | -0.26 | -0.27 | -0.2 | Upgrade
|
| Issuance of Common Stock | 0.19 | 4.16 | - | - | - | Upgrade
|
| Repurchase of Common Stock | -0.44 | -4.91 | - | - | - | Upgrade
|
| Common Dividends Paid | -2.5 | -2.47 | -1.98 | -1.24 | -1.24 | Upgrade
|
| Other Financing Activities | - | - | - | - | -0.04 | Upgrade
|
| Financing Cash Flow | -2.94 | -3.57 | -2.24 | -1.5 | -1.48 | Upgrade
|
| Foreign Exchange Rate Adjustments | 2.38 | -1.14 | 1.66 | 0.88 | -0.98 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | 0 | - | - | - | - | Upgrade
|
| Net Cash Flow | -7.18 | 3.31 | 4.48 | 38.82 | 15.94 | Upgrade
|
| Free Cash Flow | 40.8 | 31.48 | 35.88 | 39.44 | 18.41 | Upgrade
|
| Free Cash Flow Growth | 29.61% | -12.28% | -9.01% | 114.25% | 38.41% | Upgrade
|
| Free Cash Flow Margin | 42.94% | 35.70% | 45.82% | 60.01% | 38.10% | Upgrade
|
| Free Cash Flow Per Share | 0.81 | 0.62 | 0.69 | 0.76 | 0.36 | Upgrade
|
| Cash Interest Paid | - | - | - | - | 0.04 | Upgrade
|
| Cash Income Tax Paid | 15.73 | 15.65 | 7.74 | - | - | Upgrade
|
| Levered Free Cash Flow | 29.93 | 23.45 | 32.33 | 33.25 | 8.06 | Upgrade
|
| Unlevered Free Cash Flow | 32.72 | 26.23 | 34.33 | 34.67 | 9.07 | Upgrade
|
| Change in Working Capital | 2.2 | -6.44 | -3.22 | 11.96 | -10.54 | Upgrade
|
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.